J Korean Cancer Assoc.
2000 Dec;32(6):1015-1021.
Therapeutic Effect of the Intraperitoneal Cisplatin Installation (IPCI) in Advanced Gastric Carcinoma with Serosa Invasion Retrospective study
- Affiliations
-
- 1Department of Surgery, University of Ulsan College of Medicine
and Asan Medical Center, Seoul, Korea. bskim@www.amc.seoul.kr
Abstract
-
PURPOSE: We performed retrospective study to evaluate the preventive effect of intraperitoneal cisplatin installation (IPCI) on peritoneal recurrence after curative resection of advanced gastric cancer.
MATERIALS AND METHODS
The effect of IPCI was evaluated in 297 advanced gastric carcinoma
patients from January 1993 to December 1996. In IPCI group, 100 mg/body of cisplatin in one
liter of saline was installed in peritoneal cavity before wound closure in operating room and
drained out 2 hours later. Postoperative adjuvant chemotherapy with combination of 5-FU and
cisplain was performed. 155 cases were treated by IPCI. Median follow-up period was 26 months.
RESULTS
Out of 139 (46.8%) recurred cases, peritoneal, local and distant recurrences developed
in 65 (37.8%) cases, 66 (38.4%) cases and 41 (23.8%) cases respectively. In univariated analysis for survival and recurrence, IPCI, T stage and N stage were significant prognostic factors. As regards to peritoneal recurrence, IPCI and T stage were significant factors. In multivariated survival analysis, as regards to recurrence, IPCI, T stage and N stage were significant prognostic factors. As regards to peritoneal recurrence, IPCI was the only significant independent prognostic factor.
CONCLUSION
We concluded that IPCI can effectively prevent peritoneal recurrence and overall
recurrence and it shows marginal survival benefit in advanced gastric cancer patients with serosa
invasion.